| Private Placement / Financing Transactions
AIRNA: The company raised $90 million of Series A venture funding in a deal led by Forbion on July 31, 2024. ARCH Venture Partners, Ono Venture Investment, Alexandria Venture Investments, ND Capital, Fast Track Initiative, Novalis LifeSciences, Codon Capital and other undisclosed investors also participated in the round. The company’s platform is developing RNA editing therapeutics created to maximize therapeutic properties and address novel targets, enabling patients to get cures for rare and common diseases.
Jade Biosciences: The company raised $80 million of venture funding in a deal led by Venrock and Fairmount Partners on August 1, 2024. Driehaus Capital Management, Deep Track Capital, Franklin Templeton, RTW Investments and Braidwell also participated in the round. The company is an operator of a biotechnology business intended to develop therapies for patients living with autoimmune diseases.
DeepScribe: The company raised $60 million of Series B venture funding from undisclosed investors on July 30, 2024, putting the company’s pre-money valuation at an estimated $290 million. The company is a developer of an artificial intelligence-based medical scribe technology.
Healx: The company raised $47 million of Series C venture funding in a deal led by Atomico and R42 Group in August 2024. Childrens Tumor Foundation, BTOV PARTNERS S.À.R.L II, Balderton Capital, Global Brain, Ayana Capital, VU Venture Partners, Jonathan Milner and o2h also participated in the round. The company is a developer of artificial intelligence-driven drug discovery technology designed to create treatments for rare diseases.
Perceptive: The company raised $30 million of venture funding from Pacific Dental Services, Y Combinator, and Edward Zuckerberg on July 30, 2024. The company is a developer of an automated robotics technology designed to transform dental care through image-guided robotic restorative dentistry.
LTZ Therapeutics: The company raised $20 million of Series A venture funding in a deal led by Lapam Capital on July 30, 2024. K2VC, Shunwei Capital, Qiming Venture Partners, and GL Ventures also participated in the round. The company is a developer of novel immunotherapies designed to treat patients suffering from cancer and other diseases.
PineTree Therapeutics: The company raised $17 million of Series 3 venture funding in a deal led by STIC Investments and DSC Investment on July 30, 2024, putting the company’s pre-money valuation at $118 million. Quantam Finance and Acquisition, S&S Investment, Samho Green Investment, Schmidt (South Korea), Atinum Investment, and other undisclosed investors also participated in the round. The company is a developer of biological therapeutics technology designed to treat unmet needs in oncology and infectious diseases.
ZOE: The company raised $15 million of Series B venture funding from Coefficient Capital on July 29, 2024. Steven Bartlett also participated in the round. The company is a provider of medical testing services intended to deliver recommendations on personalized dietary plans for individuals.
NILO Therapeutics: The company raised $9.6 million of venture funding in the form of debt and equity from undisclosed investors on August 2, 2024. The company is an operator of a biotechnology business intended to develop therapies for autoimmune and inflammatory diseases.
Galaxy Therapeutics: The company raised $7.6 million of venture funding in the form of SAFE notes from undisclosed investors on July 31, 2024. The company is a developer of a neurovascular device designed to detect and treat cerebral aneurysms.
Scipher Medicine: The company raised $5.85 million of venture funding from undisclosed investors on July 30, 2024. The company is a developer of a precision medicine platform designed to determine which drug will work better for each patient going through an autoimmune disease.
Wisedocs: The company received CAD 4.5 million of development capital from Canadian Imperial Bank of Commerce on August 1, 2024. The company is a developer of digital operations software designed to improve the task of organizing, indexing, and reviewing medical records.
Galaxy Diagnostics: The company raised $2 million of venture funding in the form of convertible debt from Triangle Tweener Fund, Boston Harbor Angels and other undisclosed investors on July 10, 2024. The company is a developer of diagnostic tests intended for early-stage disease detection.
Glooko: The company entered into a definitive agreement to receive an undisclosed amount of development capital on August 1, 2024. The company is a developer of a remote patient-monitoring platform intended to identify at-risk patients and provide quality-enhancing interventions for people with diabetes and related chronic conditions.
iotaSciences: The company raised an undisclosed amount of venture funding from Oxford Science Enterprises and Oxford Innovation Finance on July 31, 2024. The company is a developer of a fluid-shaping technology designed to accelerate and simplify single-cell cloning.
Leal Therapeutics: The company raised an undisclosed amount of venture funding from Newpath Partners in August 2024. The company is a developer of novel therapeutics for central nervous system disorders.
Onward Therapeutics: The company raised Series A venture funding from undisclosed investors on August 2, 2024. The company is an operator of an oncology business intended to develop breakthrough medicines for the treatment of cancer.
Pharos Health: The company raised an undisclosed amount of venture funding from Moxxie Ventures in August 2024. The company is a developer of AI-powered analytics tools intended to improve hospital quality and patient safety.
SinusLogic: The company raised an undisclosed amount of venture funding from Buff Gold Ventures in August 2024. The company is a manufacturer of medical devices intended for providing treatments to chronic rhinosinusitis patients.
Syndesis Health: The company raised an undisclosed amount of venture funding from AI Capital in August 2024. The company is an operator of a biotechnology research business intended to offer life sciences research and innovation for biotechs, pharma, and research organizations.
|
